PDS Biotechnology has entered into a licensing agreement with Merck KgaA, Germany, for use of PDS Biotechnology's Versamune nanotechnology platform. Under the terms of the agreement, Merck will obtain the rights to use the technology ...
Tags: Versamune nanotechnology platform, company cooperation